- United States
- Biologic innovation
Biologic innovation
Complex medicines with a common vision. At J&J Innovative Medicine, we have a deep responsibility to the people we serve, and we work tirelessly to advance and improve how medicines are discovered, developed and made.
What is a biologic?
Biological products are a diverse category of products and are generally large, complex molecules. These are produced through biotechnology in a living system, such as a microorganism, plant cell, or animal cell. In comparison to a conventional drug like aspirin that is made from chemical compounds and can be duplicated easily.
What is an unbranded biologic?
An unbranded biologic is an approved brand-name biologic being marketed under its approved biologics license without the brand-name. It is considered by the FDA to be the same product as the brand-name biologic under the same biologics license and has the same strength, dosage form, route of administration, and presentation as the brand-name biologic.
What is a biosimilar?
A biosimilar is a biological product that is produced from a different cell line, is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.
Patient and provider choice
We are concerned about clinically stable patients being switched to another therapy for non-medical reasons - reasons not related to health, product efficacy or safety. We aim to deliver solutions that provide value to the patients, physicians and the healthcare system, including greater access and treatment choice.
We believe treatment decisions belong in the hands of patients and their physicians, who best understand the patient’s medical history, condition and treatment needs. We believe patients should have affordable access to appropriate treatment options and sites of care.
Some studies have been conducted to evaluate the implications of non-medical switching on patients and show varying results. To learn more about Janssen’s commitment to advancing solutions that strengthen the U.S. healthcare system, read our U.S. Transparency Report.